$Bioxcel Therapeutics Inc.(BTAI)$Shares of BioXcel Therapeutics Inc. (BTAI) jumped 14.6% in premarket trading on Wednesday after the company said the Food and Drug Administration approved Igalmi, a sublingual film used to treat agitation associated with schizophrenia or bipolar disorder in adults. The therapy is expected to launch in the U.S. in the second quarter of this year. BioXcel's stock is down 2.2% so far this year, while the broader S&P 500 has declined 5.0%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments
[Miser]